摘要
目的:探讨地西他滨(DAC)联合预激方案初次治疗高危骨髓增生异常综合征(MDS)及老年急性髓系白血病(AML)的疗效和不良反应。方法:回顾性分析首次接受DAC联合预激方案(DAC 25 mg qd,d_(1~5);Ara-C 10 mg/m^2q12h,d_(6~12); Acla 12 mg/m^2qd,d_(6~9); G-CSF 200μg/m^2qd,WBC> 20×10~9/L则停用)治疗26例高危MDS及老年AML患者的疗效和不良反应。结果:26例高危MDS及老年AML患者中,完全缓解率42. 3%,总体反应率(完全缓解+部分缓解) 65. 4%,中位生存时间为16. 2个月。结论:DAC联合预激方案治疗高危MDS及老年AML患者疗效确切,且安全性高,但由于本研究样本量较小,需进一步开展多中心随机对照试验证实。
Objective To explore the efficacy and side effects of decitabine( DAC) combined with CAG regimen for high-risk myelodysplastic syndrome( MDS) and elderly acute myeloid leukemia( AML). Methods: A retrospective analysis was performed on the efficiency and side effects of DAC combined with CAG regimen( DAC 25 mg qd,d1~5,Ara-C 10 mg/m^2 q12 h,d6~12,Acla 12 mg/m^2 qd,d6~9,G-CSF 200 μg/m^2 qd,WBC > 20 × 10^9/L then stop)for 26 cases of high-risk MDS and elderly AML. Results: Among the 26 cases of high-risk MDS and elderly AML,complete remission( CR) rate was 42. 3%. The clinical efficiency( CR + PR) was 65. 4%. None of the patients died early. Median survival time was 16. 2 months. Conclusion: The DAC combined with CAG regimen for high-risk MDS and elderly AML patients had definite therapeutic effect,and high safety. Due to the small sample cohort,multicenter randomized controlled trial is necessary.
作者
凌奕文
叶海燕
赵莹
陈焯文
Ling Yiwen;Ye Haiyan;Zhao Ying;Chen Zhuowen(Department of Hematology, The First Peoples Hospital of Foshan (Affiliated Foshan Hospital of Sun Yat - Sen University) ,Guangdong Foshan 528000, China)
出处
《现代肿瘤医学》
CAS
2019年第2期321-324,共4页
Journal of Modern Oncology